MTOR and plasma cell myeloma: The dual PI3K/mTOR inhibitor, BGT226, has been investigated for the treatment of hematological malignancies, such as acute lymphoblastic leukemias [19, 52], alone, in combination or in comparison with other drugs such as gefitinib or NVP-BEZ235 in different solid tumor models, including non-small cell lung cancer, head and neck squamous cell carcinoma, pancreatic cancer, multiple myeloma and breast cancer [11, 26, 29, 53].